Bioinformatics Articles
-
AI, Digitalization, And In Vivo Programming Redefine Cell And Gene Therapy
4/20/2026
By merging precision genetic engineering with the scalability of nanomedicine and the predictive power of AI, scientists are reshaping the future of human health.
-
AI Drug Discovery Is Revealing The Preclinical Bottleneck
4/8/2026
For the generative AI revolution in drug discovery to deliver on its promise, the industry needs more than better molecules, it needs a better pipeline architecture.
-
NAMs In France And Europe: The Current Landscape
3/20/2026
The EU is establishing a credible and scalable NAM ecosystem, but challenges still need to be overcome before life sciences professionals and patients can reap the benefits.
-
New Approach Methods In Practice: Where Are We Today?
2/10/2026
NAMs have moved beyond a technological promise, but now the current challenge is to operationalize their adoption.
-
AI For NAM-Ready Drug Development: Turning Promise Into Trust
1/30/2026
AI is naturally situated for NAMs, and its value will be maximized when it is deployed as part of a rigorously validated, evidence-based strategy.
-
Charting The Future Of Antimicrobial Resistance
1/21/2026
We caught up with Ajit Parhi, Ph.D., CSO of TAXIS Pharmaceuticals, to discuss policy, precision science, and AI in battling antimicrobial resistance.
-
Annual Reflections And Predictions From The Editors' Roundtable
1/6/2026
Understanding the full scope of the life science industry has never been more critical. Ray Dogum, Chief Editor of Drug Discovery Online, joins the Life Science Connect Editors’ Roundtable on a special episode of Better Biopharma podcast.
-
2025's Top 5 Drug Discovery Highlights And How To Stay Ahead In 2026
12/15/2025
Drug Discovery Online's 2025 Top 5 most consequential shifts affecting this rapidly evolving field, including NAMs, AI, Individualized Therapies, Innovating China, and Early-stage Funding Volatility.
-
From Funding Gaps to AI Frontiers: Insights from the Boston Globe Summit 2025
11/20/2025
Insights from the Boston Globe Summit 2025 exploring biotech funding challenges, AI-driven drug discovery, and genome editing breakthroughs shaping the future of research and care.
-
Live Insights: 45% Believe The NAMs Industry Should Expand Pre-Competitive Data Sharing Programs
11/13/2025
According to a recent poll, 45% of participants believe the NAMs industry should expand pre-competitive consortia by sharing validation data and best practices to reduce duplication and accelerate acceptance. Experts Zahar Nahle, Ph.D. and Samantha Atkins, Ph.D. share their insights.